[{"data":1,"prerenderedAt":173},["ShallowReactive",2],{"story-11023-tw":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":30,"questions":31,"relatedArticles":41,"body_color":171,"card_color":172},"11023",null,"策略性價格戰：諾和諾德在中國藥品市場的先發制人防禦","藥品定價策略，預示跨境醫療賣家在全球市場的適應",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,10,23,24,25,26,17,27,14,28,29],"https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1TdhZR.img?w=768&h=512&m=6","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://pubimg.futunn.com/2022050900000138b797f787435.jpg","https://imgproxy.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/18839540/4h2vir/ALTERNATES/master-3_2/totw-obesity","https://static.gurufocus.com/cdn-cgi/image/width=500,quality=100/1993375832453849088.jpg","https://img.36krcdn.com/hsossms/20251225/v2_bc193553c38d47a0b8fe65f5dfc37eeb@5930287_oswg44397oswg852oswg448_img_jpg?x-oss-process=image/quality,q_100/format,jpg/interlace,1","https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/large_novo_nordisk_resized_ebdb16c103.jpg","https://static.gurufocus.com/cdn-cgi/image/width=500,quality=100/logos/0C00000BWS.png?20","https://www.devdiscourse.com/remote.axd?https://devdiscourse.blob.core.windows.net/aiimagegallery/18_07_2025_08_39_36_026596.png?width=1280","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1TeFsT.img?w=1536&h=1024&m=4&q=71","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1723849668/image_1723849668.jpg?io=getty-c-w1280","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iIfVjg0NIxR8/v3/620x-1.jpg","https://www.reuters.com/resizer/v2/TU4IYZCYVFLGZM2YMJXR5BCLAU.jpg?auth=fb262110fb863304236275356809cd7082f2681edc534d4c0293f10107fe130e&width=1920&quality=80","https://www.globalbankingandfinance.com/_next/image/?url=https%3A%2F%2Fimagedelivery.net%2FMkQ8HKvpw9EqULcU_pSqWg%2Fcloud-ea964e8a-12a1-473f-96a1-ead6b50d5c23%2Fpublic&w=3840&q=75","https://storage.googleapis.com/media.mwcradio.com/mimesis/2025-12/29/2025-12-29T125614Z_1_LYNXMPELBS0GQ_RTROPTP_3_CHINA-NOVONORDISK.JPG","https://images.cnbctv18.com/uploads/2024/06/ozempic-2-2024-06-0b16a3b3e269559e193e0d935a916e12.jpg?impolicy=website&width=1200&height=900","https://www.geneonline.com/wp-content/uploads/EN_Mobile_Dec_HIV_AIDS-450x350.png","http://img.yicaiglobal.com/src/image/2025/12/107526759131845.jpg","https://cdn.benzinga.com/files/images/story/2025/12/29/Wegovy.jpeg?width=1200&height=800&fit=crop","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/i0ld2bbkcKA0/v0/1920x1080.png","在震盪全球製藥生態系統的精心算計下，**諾和諾德**正在改寫市場防禦策略，透過策略性地調降其減肥藥**Wegovy**在中國的價格。這不僅僅是價格調整，而是一場旨在維持在競爭日益激烈的環境中市場主導地位的複雜地緣政治棋局。\n\n其核心策略揭示了對專利到期管理的細緻入微的處理方式。透過對最高劑量級別進行**37-48%的降價**，諾和諾德正在建立一道強大的屏障，以對抗新興的仿製藥競爭對手。在雲南和四川等省份，價格降幅從987-1,284元人民幣不等，這不僅僅是成本控制，更是一種針對潛在市場破壞的先發制人。\n\n更廣泛的背景同樣引人注目。到**2030年**，中國的肥胖市場預計將涵蓋其14億人口的**65%以上**，這使得這次定價策略從防禦性策略轉變為關鍵的市場定位策略。**石藥集團**和**杭州九源基因工程有限公司**等本土藥廠正在準備仿製藥，這使得諾和諾德的早期定價干預具有策略上的出色性。\n\n這種方法與該公司在全球範圍內的策略相似，此前已在印度和美國進行了類似的價格調整。它表明，在新興醫療保健市場中，主動定價可能比專利保護更有效。對於跨境電商賣家來說，這代表了一堂關於適應性市場策略的經典課程，展示了製藥公司如何透過智慧、前瞻性的定價機制來維持市場領先地位。\n\n其影響遠遠超出了單一藥品或市場。此舉代表了製藥競爭的新範式，其中策略性定價成為維持市場相關性和客戶忠誠度的主要武器。",[32,35,38],{"title":33,"answer":34,"author":5,"avatar":5,"time":5},"諾和諾德為何在專利到期前，就調降Wegovy在中國的價格？","諾和諾德積極捍衛其市場地位，為學名藥競爭者設立進入壁壘。透過在 2026 年專利到期前將價格降低 37-48%，他們旨在留住客戶忠誠度，並讓本土藥廠難以有效競爭。",{"title":36,"answer":37,"author":5,"avatar":5,"time":5},"這種定價策略會如何影響跨境藥品賣家？","這項策略預示著重大的市場轉變，為賣家創造了理解適應性定價模型的機會。這表明製藥電子商務平台應為更具動態性的定價環境做好準備，並可能探索與創新藥物製造商的合作關係。",{"title":39,"answer":40,"author":5,"avatar":5,"time":5},"中國肥胖藥物市場有什麼特別吸引之處？","隨著預測顯示，到 2030 年，中國 14 億人口中可能有超過 65% 的人超重，肥胖藥物市場代表著巨大的增長機會。 這個龐大的潛在市場使得藥品公司的策略定價和早期市場定位至關重要。",[42,47,51,55,59,63,67,70,74,78,82,86,89,93,97,100,104,107,111,115,119,123,126,130,133,138,141,146,150,155,158,163,167],{"id":43,"title":44,"source":45,"logo":10,"time":46},172767,"Novo Nordisk cuts price of weight-loss drug Wegovy in China","https://www.msn.com/en-us/money/markets/novo-nordisk-cuts-price-of-weight-loss-drug-wegovy-in-china/ar-AA1TdSl9","2天前",{"id":48,"title":49,"source":50,"logo":5,"time":46},172768,"Novo Nordisk Halves Prices of Obesity Drug in Parts of China","https://www.marketscreener.com/news/novo-nordisk-halves-prices-of-obesity-drug-in-parts-of-china-ce7e59dbdd80f721",{"id":52,"title":53,"source":54,"logo":5,"time":46},172769,"Novo Nordisk Confirms Price Adjustment for Wegovy in China","https://www.marketscreener.com/news/novo-nordisk-confirms-price-adjustment-for-wegovy-in-china-ce7e59dbdd8efe23",{"id":56,"title":57,"source":58,"logo":5,"time":46},172763,"Novo Nordisk Halves Wegovy Prices in China - Yicai","https://www.marketscreener.com/news/novo-nordisk-halves-wegovy-prices-in-china-yicai-ce7e59dbda81ff21",{"id":60,"title":61,"source":62,"logo":20,"time":46},173577,"Novo Nordisk cuts Wegovy price in China","https://seekingalpha.com/news/4535732-novo-nordisk-cuts-wegovy-price-china",{"id":64,"title":65,"source":66,"logo":24,"time":46},172764,"Novo cuts Wegovy prices in some Chinese provinces, local media reports","https://whtc.com/2025/12/29/novo-cuts-wegovy-prices-in-some-chinese-provinces-local-media-reports/",{"id":68,"title":44,"source":69,"logo":10,"time":46},173578,"https://www.msn.com/en-us/money/markets/novo-nordisk-cuts-price-of-weight-loss-drug-wegovy-in-china/ar-AA1TdSvc",{"id":71,"title":72,"source":73,"logo":14,"time":46},172765,"Novo Nordisk Cuts Wegovy Prices in China Ahead of Patent Expirat","https://www.gurufocus.com/news/4088470/novo-nordisk-cuts-wegovy-prices-in-china-ahead-of-patent-expiration",{"id":75,"title":76,"source":77,"logo":29,"time":46},173579,"Stock Movers: Novo Nordisk, Praxis Precision, Lululemon","https://www.bloomberg.com/news/audio/2025-12-29/stock-movers-novo-praxis-precision-lululemon-podcast",{"id":79,"title":80,"source":81,"logo":28,"time":46},172766,"What's Going On With Novo Nordisk Stock Monday? - Novo Nordisk (NYSE:NVO)","https://www.benzinga.com/news/health-care/25/12/49613534/novo-nordisk-halves-wegovy-prices-in-china-ahead-of-generic-threat",{"id":83,"title":84,"source":85,"logo":17,"time":46},172760,"Novo Nordisk (NVO) Reduces Wegovy Prices in China Amid Competiti","https://www.gurufocus.com/news/4087825/novo-nordisk-nvo-reduces-wegovy-prices-in-china-amid-competition-concerns",{"id":87,"title":84,"source":88,"logo":5,"time":46},173574,"https://www.gurufocus.com/news/4087825/novo-nordisk-nvo-reduces-wegovy-prices-in-china-amid-competition-concerns?mobile=true",{"id":90,"title":91,"source":92,"logo":5,"time":46},172761,"Novo Nordisk reportedly cut Wegovy prices in China by half","https://ca.investing.com/news/stock-market-news/novo-nordisk-reportedly-cut-wegovy-prices-in-china-by-half-4379498",{"id":94,"title":95,"source":96,"logo":26,"time":46},173575,"Novo Nordisk to Market Wegovy at Lower Price Than Eli Lilly’s Obesity Drug","https://www.geneonline.com/novo-nordisk-to-market-wegovy-at-lower-price-than-eli-lillys-obesity-drug/",{"id":98,"title":91,"source":99,"logo":5,"time":46},172762,"https://www.investing.com/news/stock-market-news/novo-nordisk-reportedly-cut-wegovy-prices-in-china-by-half-4423660",{"id":101,"title":102,"source":103,"logo":17,"time":46},173576,"Novo Nordisk (NVO) Slashes Wegovy Prices in China Ahead of Paten","https://www.gurufocus.com/news/4088982/novo-nordisk-nvo-slashes-wegovy-prices-in-china-ahead-of-patent-expiry",{"id":105,"title":44,"source":106,"logo":22,"time":46},172914,"https://www.reuters.com/business/healthcare-pharmaceuticals/novo-cuts-wegovy-prices-some-chinese-provinces-local-media-reports-2025-12-29/",{"id":108,"title":109,"source":110,"logo":21,"time":46},172915,"Novo Nordisk Cuts China Wegovy Price Before Patent Expiry","https://www.bloomberg.com/news/articles/2025-12-29/novo-cuts-china-wegovy-price-before-patent-expiry-yicai-reports",{"id":112,"title":113,"source":114,"logo":18,"time":46},172757,"Novo Nordisk's Strategic Price Cuts and the Consumerization of Weight Loss Drugs","https://www.devdiscourse.com/article/science-environment/3744379-novo-nordisks-strategic-price-cuts-and-the-consumerization-of-weight-loss-drugs",{"id":116,"title":117,"source":118,"logo":16,"time":46},172758,"Novo Nordisk Slashes Weight Loss Drug Price By Up To 50% In China: Report","https://stocktwits.com/news-articles/markets/equity/novo-nordisk-slashes-weight-loss-drug-price-by-up-to-50-percent-in-china/cL75tbYREDz",{"id":120,"title":121,"source":122,"logo":27,"time":46},172759,"Weight-Loss Drug Prices Drop in China as Patent Expiry Nears","https://www.yicaiglobal.com/news/prices-of-imported-glp-1-weight-loss-drugs-halve-as-patent-protection-in-china-to-expire",{"id":124,"title":44,"source":125,"logo":23,"time":46},172913,"https://www.globalbankingandfinance.com/china-novonordisk/",{"id":127,"title":128,"source":129,"logo":5,"time":46},172770,"Novo cuts listing prices for Wegovy in some Chinese provinces, Bloomberg says","https://www.tipranks.com/news/the-fly/novo-cuts-listing-prices-for-wegovy-in-some-chinese-provinces-bloomberg-says-thefly",{"id":131,"title":91,"source":132,"logo":5,"time":46},174475,"https://ng.investing.com/news/stock-market-news/novo-nordisk-reportedly-cut-wegovy-prices-in-china-by-half-2268225",{"id":134,"title":135,"source":136,"logo":15,"time":137},172771,"Tirzepatide, the \"Drug King\", Sees 70% Price Cut, Transforming Blood Sugar Control and Weight Loss Markets","https://eu.36kr.com/en/p/3610505415574532","5天前",{"id":139,"title":61,"source":140,"logo":19,"time":46},174476,"https://www.msn.com/en-us/money/topstocks/novo-nordisk-cuts-wegovy-price-in-china/ar-AA1TeRes",{"id":142,"title":143,"source":144,"logo":12,"time":145},172772,"Price cuts of 50% and 20%! Collective price reductions for Semaglutide and Tirzepatide signal intensified competition in weight-loss drugs by 2026.","https://news.futunn.com/en/post/66688403/price-cuts-of-50-and-20-collective-price-reductions-for","4天前",{"id":147,"title":148,"source":149,"logo":14,"time":137},174477,"Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access","https://www.gurufocus.com/news/4087186/lilly-and-novo-cut-glp1-prices-as-pill-approvals-expand-access?mobile=true",{"id":151,"title":152,"source":153,"logo":13,"time":154},172773,"Novo Nordisk’s Wegovy approved for cardiovascular disease treatment in China","https://medwatch.com/News/Pharma___Biotech/article18872165.ece","8天前",{"id":156,"title":148,"source":157,"logo":5,"time":137},173580,"https://finance.yahoo.com/news/lilly-novo-cut-glp-1-130129689.html",{"id":159,"title":160,"source":161,"logo":25,"time":162},174473,"Novo Nordisk slashes Wegovy price in China before patent expiry amid rising copycats","https://www.cnbctv18.com/business/novo-nordisk-slashes-wegovy-price-in-china-before-patent-expiry-amid-rising-copycats-19807500.htm","1天前",{"id":164,"title":165,"source":166,"logo":5,"time":46},173682,"Novo Nordisk Cuts Wegovy Prices in China Ahead of Patent Expiration","https://finance.yahoo.com/news/novo-nordisk-cuts-wegovy-prices-174517972.html",{"id":168,"title":169,"source":170,"logo":11,"time":162},174474,"Key facts: Novo Nordisk cuts Wegovy prices in China by up to 48%; faces supply issues","https://www.tradingview.com/news/tradingview:a9d994ee30824:0-key-facts-novo-nordisk-cuts-wegovy-prices-in-china-by-up-to-48-faces-supply-issues/","#e6eeedff","#e6eeed4d",1767249077478]